Literature DB >> 3991877

Ten years' experience of an amyloid clinic--a clinicopathological survey.

M J Browning, R A Banks, C R Tribe, P Hollingworth, C Kingswood, J C Mackenzie, P A Bacon.   

Abstract

The aetiology, clinical course and affected organs were studied in 124 patients with acquired systemic amyloidosis and seven patients with organ-limited amyloid deposits. Seventy-five patients had reactive systemic AA amyloidosis, which was associated with rheumatic disease in 55 and with chronic infection in 13 cases. Forty-nine patients had systemic AL amyloidosis. Thirteen of these cases were associated with myelomatosis and 11 with non-malignant immunocyte dyscrasias. In 25 patients with systemic AL disease no immunocyte dyscrasia was identified. Renal involvement dominated the clinical course of both forms of systemic amyloidosis, and renal failure was the most common cause of death. Gastrointestinal disturbance and hepatosplenomegaly were found in both AA and AL disease, although differences were noted in the distribution of amyloid protein within rectal biopsies. Amyloid cardiomyopathy, neuropathy and macroglossia were present in patients with AL amyloidosis only. These clinical patterns were reflected by tissue distribution at necropsy in 67 patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3991877

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  22 in total

1.  Primary localized amyloidosis of the urinary bladder.

Authors:  Hiroki Kato; Hisao Toei; Makoto Furuse; Kazumi Suzuki; Mitsugu Hironaka; Ken Saito
Journal:  Eur Radiol       Date:  2003-01-18       Impact factor: 5.315

2.  [Amyloid diagnostics in rheumatic diseases].

Authors:  C Röcken; J Ernst
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

3.  The course of renal amyloidosis with uraemia.

Authors:  B Lindqvist; S Andersen; B Isacsson; E Lundberg
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

Review 4.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

5.  Determination of IgA- and IgM-rheumatoid factors in patients with rheumatoid arthritis with and without nephropathy.

Authors:  M Nakano; M Ueno; S Nishi; S Suzuki; H Hasegawa; T Watanabe; T Kuroda; S Ito; M Arakawa
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

6.  AA amyloidosis associated with systemic lupus erythematosus.

Authors:  E J ter Borg; S Janssen; M H van Rijswijk; J Bijzet; P E de Jong; J D Elema; C G Kallenberg
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

7.  Impaired splenic function in systemic amyloidosis.

Authors:  C D Selby; V M Sprott; P J Toghill
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

8.  Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis.

Authors:  Y Okuda; K Takasugi; T Oyama; H Oyama; S Nanba; T Miyamoto
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

9.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; A P Maxwell; I Bruce; B G Murphy; C C Doherty
Journal:  Ir J Med Sci       Date:  1993-06       Impact factor: 1.568

10.  Surgical complications of amyloid disease.

Authors:  D P O'Doherty; J P Neoptolemos; D C Bouch; K F Wood
Journal:  Postgrad Med J       Date:  1987-04       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.